Prosecution Insights
Last updated: April 19, 2026
Application No. 18/149,649

METHODS FOR DELIVERY OF THERAPEUTIC MATERIALS TO TREAT CANCER

Non-Final OA §103
Filed
Jan 03, 2023
Examiner
SHAH, NILAY J
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Renovorx Inc.
OA Round
3 (Non-Final)
77%
Grant Probability
Favorable
3-4
OA Rounds
3y 3m
To Grant
99%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allow Rate
439 granted / 571 resolved
+6.9% vs TC avg
Strong +47% interview lift
Without
With
+47.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
76 currently pending
Career history
647
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
45.5%
+5.5% vs TC avg
§102
20.3%
-19.7% vs TC avg
§112
27.5%
-12.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 571 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 12/8/2025 has been entered. Response to Amendment The Amendment filed 12/8/2025 has been entered. Claims 2-20 remain pending in the application. Applicant’s amendments to the Claims have overcome each and every objection previously set forth in the Final Office Action mailed 10/7/2025. Information Disclosure Statement The information disclosure statement filed 12/31/2025 fails to comply with 37 CFR 1.98(a)(2), which requires a legible copy of each cited foreign patent document; each non-patent literature publication or that portion which caused it to be listed; and all other information or that portion which caused it to be listed. It has been placed in the application file, but the information referred to therein has not been considered. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 2, 4-6 and 11 are rejected under 35 U.S.C. 103 as being unpatentable over Garrison et al. (US 2005/0059931 A1) in view of Andreas et al. (US 2005/0149159 A1) and further in view of Looper et al. (US 2013/0281971 A1). Regarding claim 2, Garrison discloses an apparatus (figure 1A), comprising: an inner catheter 2 defining an inner catheter lumen 17 (figures 3, 4, 7) configured to receive a guidewire (paragraph 0045, lines 8-11); an outer catheter 4 defining a first lumen 20 (figure 5, paragraph 0049, lines 2-5) configured to introduce a therapeutic material to one or more target vessels, and a second lumen 13 (paragraph 0047) configured to slidably receive at least a portion of the inner catheter; a first occluder 3 coupled to the inner catheter 2; a second occluder 5 coupled to the outer catheter 4, the second occluder 5 disposed proximal to the first occluder 3, a distance between the first occluder and the second occluder being adjustable (paragraph 0006, lines 11-15); a pressure transducer (paragraph 0045, lines 11-15) configured to detect a pressure within the target vessel between the first occluder 3 and the second occluder 5 and configured to guide delivery of the therapeutic material to the one or more target vessels (paragraph 0019, lines 2-13, “configured to guide delivery” is pretty broad term and would also mean to recite rate of delivery to prevent exceeding maximum pressure as explained by Garrison) but is silent regarding a handle, configured to allow for single handed operation of the apparatus, the handle comprising an actuator on the handle that includes a set of protrusions that are configured to be sequentially engaged as the actuator is moved between a plurality of predetermined settings corresponding to predetermined distances between an end portion of the outer catheter and an end portion of the inner catheter, further wherein the handle comprises a visual indicator of the predetermined settings indicating a position of the actuator. However, Andreas teaches a design of devices and methods for controlling and indicating the length of an interventional element comprising a handle 28 (figure 2A, examiner construes element 56 being part of element 28), configured to allow for single handed operation of the apparatus (element 28 would allow single handed operation), the handle 28 comprising an actuator 58 on the handle that includes a set of markings 60 that are configured to be sequentially engaged as the actuator is moved between a plurality of predetermined settings (paragraph 0063, paragraph 0065, lines 32-35) corresponding to predetermined distances between an end portion of the outer catheter 38 and an end portion of the inner catheter 36, further wherein the handle 28 comprises a visual indicator 60 (paragraph 0073, lines 11-13) of the predetermined settings indicating a position of the actuator and configured to determine a desired distance to move the actuator for the purpose of having improved ways of controlling and providing indication of balloon length (paragraph 0010). Therefore, it would have been prima facie obvious to one of ordinary skill in the art, before the effective filing of the claimed invention to modify the apparatus of Garrison to incorporate a handle, configured to allow for single handed operation of the apparatus, the handle comprising an actuator on the handle that includes a set of protrusions that are configured to be sequentially engaged as the actuator is moved between a plurality of predetermined settings corresponding to predetermined distances between an end portion of the outer catheter and an end portion of the inner catheter, further wherein the handle comprises a visual indicator of the predetermined settings indicating a position of the actuator as taught by Andreas for the purpose of having improved ways of controlling and providing indication of balloon length (paragraph 0010). While Andreas discloses the visual indicator 60 could include alphanumeric symbols or other appropriate indicators (paragraph 0063, lines 2-5), Garrison modified in view of Andreas is silent regarding a set of protrusions and wherein the visual indicator corresponds with the protrusions associated with the plurality of predetermined settings. However, Looper teaches a design of a catheter allowing variable dosing including a set of markings and visual indicator 21 (figure 1) comprising a set of protrusions (paragraph 0017, lines 1-4) and wherein the visual indicator (examiner construes that “visual indicator” corresponds to the numbers associated with the lines and protrusions refers to lines in graduated marking) corresponds with the protrusions associated with the plurality of predetermined settings for the purpose of using a well-known approaches in placing the protrusions and visual markers on medical device (paragraph 0017, figure 1). Therefore, it would have been prima facie obvious to one of ordinary skill in the art to modify the set of markings and visual indicator of Garrison in view of Andreas to incorporate a set of protrusions and wherein the visual indicator corresponds with the protrusions associated with the plurality of predetermined settings as taught by Looper for the purpose of using a well-known approach in placing the protrusions and visual markers on medical device (paragraph 0017, figure 1). Regarding claim 4, Garrison discloses wherein the first occluder 3 includes one of an expandable filter and an inflatable balloon (figure 1A). Regarding claim 5, Garrison discloses wherein the first occluder 3 and the second occluder 5 define an isolated region of the target vessel, the first lumen 20 of the outer catheter is configured to allow atraumatic introduction of therapeutic cells into the isolated region (element 20 is configured to perform the claimed function). Regarding claim 6, Garrison discloses wherein the first lumen 20 of the outer catheter 4 is configured to allow rapid infusion of the therapeutic material (element 20 is configured to perform the claimed function). Regarding claim 11, Garrison discloses the distance between the first occluder and the second occluder is adjustable (paragraph 0065, lines 5-8). However, Garrison does not explicitly disclose the distance between the first occluder and the second occluder is adjustable between 3 cm and 15 cm. There is no evidence of record that establishes that changing the distance would result in a difference in a function of Garrison. Further, a person having ordinary skill in the art, being faced with modifying the distance between the first occluder and the second occluder would have a reasonable expectation of success in making such a modification and it appears that the device would function as intended being given the claimed distance range. Lastly, applicant has not disclosed that the claimed range solves any stated problem, indicating that the distance “may” be within the claimed range, and offering other ranges (3 cm to 22 cm, paragraph 0073) and therefore, there appears to be no criticality placed on the range as claimed such that it produces an unexpected result. Therefore, it would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to modify the distance of Garrison to have the distance between 3 cm and 15 cm as an obvious matter of design choice within the skill of the art. Claims 3, 7 and 8 are rejected under 35 U.S.C. 103 as being unpatentable over Garrison et al. (US 2005/0059931 A1) in view of Andreas et al. (US 2005/0149159 A1) in view of Looper et al. (US 2013/0281971 A1) and further in view of Slater et al. (US 2006/0149218 A1). Regarding claim 3, Garrison/Andreas/Looper (hereinafter referred as “modified Garrison”) discloses the claimed invention substantially as claimed, as set forth above in claim 2. Garrison is silent regarding further comprising a seal coupled to the outer catheter and configured to prevent therapeutic material from entering the second lumen of the outer catheter. However, Slater teaches a design (figure 34) of treating the interior of a blood vessel comprising a seal 1104 (figure 34) coupled to the outer catheter 1100 and configured to prevent therapeutic material (material infused into element 1100) from entering the second lumen of the outer catheter for the purpose of preventing the flow of the fluid out from the distal end of the second lumen (figure 34, paragraph 0152, lines 1-4). Therefore, it would have been prima facie obvious to one of ordinary skill in the art, before the effective filing of the claimed invention to modify the apparatus of Garrison to incorporate further comprising a seal coupled to the outer catheter and configured to prevent therapeutic material from entering the second lumen of the outer catheter as taught by Slater for the purpose of preventing the flow of the fluid out from the distal end of the second lumen (figure 34, paragraph 0152, lines 1-4). Regarding claim 7, modified Garrison discloses the claimed invention substantially as claimed, as set forth above in claim 2. Garrison discloses the distance between the second occluder and the first occluder being adjustable (paragraph 0006, lines 11-15). Furthermore, Garrison modified in view of Slater as explained in the rejection of claim 3 above would result in placing the seal of Slater at the distal end of the outer catheter. Therefore, the modified device of Garrison in view of Slater will result in having the distance between the first occluder and the seal can be adjusted. Regarding claim 8, modified Garrison discloses the claimed invention substantially as claimed, as set forth above in claim 2. Garrison further discloses wherein the second occlude and the seal collectively have a diameter between 2mm and 12mm (paragraph 0140, the seal of Slater when incorporated into the diameter as explained in the rejection of claim 3 above would not really contribute too much into diameter of the catheter or the balloon due to the design and placement of the seal). Claim(s) 9 is rejected under 35 U.S.C. 103 as being unpatentable over Garrison et al. (US 2005/0059931 A1) in view of Andreas et al. (US 2005/0149159 A1) in view of Looper et al. (US 2013/0281971 A1) and further in view of Hiblar et al. (US 2002/0072706 A1). Regarding claim 9, modified Garrison discloses the claimed invention as claimed as set above in claim 1 above. Garrison further discloses further comprising the therapeutic material (paragraph 0038, lines 17-24, “cells”). However, modified Garrison is silent regarding wherein the therapeutic material includes stem cells. However, Hiblar teaches a design of a drug delivery catheter (figure 1) wherein the therapeutic material includes stem cells (paragraph 0043) for the purpose of treating the medical condition/disorder requiring the delivery of the stem cells (paragraphs 0040, 0043). Therefore, it would have been prima facie obvious to one of ordinary skill in the art, before the effective filing of the claimed invention to modify the therapeutic material of modified Garrison to incorporate wherein the therapeutic material includes stem cells as taught by Hiblar for the purpose of treating the medical condition/disorder requiring the delivery of the stem cells (paragraphs 0040, 0043). Claim(s) 10, 12, 13, 14 and 16-20 are rejected under 35 U.S.C. 103 as being unpatentable over Garrison et al. (US 2005/0059931 A1) in view of Andreas et al. (US 2005/0149159 A1) in view of Looper et al. (US 2013/0281971 A1) and further in view of Zadno-Azizi et al. (US 2002/0016565). Regarding claim 10, modified Garrison discloses the claimed invention substantially as claimed, as set forth above in claim 2. Garrison further discloses further comprising an adapter (see “A” in fig. 2A below), the adapter including a first port (see “FP” in figure 2A below) and a second port (see “SP” in figure 2A below) but is silent regarding the first port in fluid communication with the first lumen through which the therapeutic agent can be conveyed to a region of the vessel isolated by the first occluder and the second occluder, the second port in fluid communication with the second lumen. PNG media_image1.png 292 786 media_image1.png Greyscale However, Zadno-Azizi teaches a design of a catheter (figure 3) comprising an adapter 112 having the first port 120 and the second port 123, the first port in fluid communication with the lumen 130 through which the therapeutic agent can be conveyed to a region of the vessel (paragraph 0068, lines 14-17) and the second port 123 in fluid communication with the lumen 130 for the purpose of using the ports to introduce therapeutic agents into the patient’s body and the medical device (paragraph 0068, lines 2-17). Examiner further construes that even though Zadno-Azizi discloses the use of different port to access same lumen 130, Garrison discloses different lumen and ports. Therefore, one of ordinary skill in the art, modifying the device of Garrison in view of Zadno-Azizi would result in having the first port in fluid communication with the first lumen through which the therapeutic agent can be conveyed to a region of the vessel isolated by the first occluder and the second occluder, the second port in fluid communication with the second lumen. Therefore, it would have been prima facie obvious to one of ordinary skill in the art, before the effective filing of the claimed invention to define the function of the ports of the device of Garrison to incorporate the first port in fluid communication with the first lumen through which the therapeutic agent can be conveyed to a region of the vessel isolated by the first occluder and the second occluder, the second port in fluid communication with the second lumen as taught by Zadno-Azizi for the purpose of using the ports to introduce therapeutic agents into the patient’s body and the medical device (paragraph 0068, lines 2-17). Regarding claim 12, Garrison discloses an apparatus (figure 1A) comprising: an inner catheter 2 defining an inner catheter lumen 17 (figures 3, 4, 7) configured to receive a guidewire (paragraph 0045, lines 8-11); a first occluder 3 coupled to the inner catheter 2 at a first axial location (location where element 3 is positioned with respect to element 2) along the inner catheter 2; an outer catheter 4 including a side wall (wall of element 19A forming element 20 in figure 5) defining an infusion aperture (an aperture in element 20 that delivers the fluid, furthermore, claim recites the term “defining” which do not necessarily mean to have an infusion aperture located on sidewall only, instead examiner construes the term “defining” as being able to define at least a portion of an aperture. In Garrison, sidewall of element 20 is at least partially defining the opening through which fluid gets delivered), the outer catheter 4 defining a first lumen 20 in fluid communication with the infusion aperture (opening in element 20 delivering the fluid to the patient) and a second lumen 13 (paragraph 0047), at least a portion of the inner catheter 2 being slidably disposed within the second lumen 13; a second occluder 5 coupled to the outer catheter 4 at a second axial location (location of element 5 with respect to element 4) along the catheter device (figure 1A), the second axial location spaced apart from the first axial location (figure 1A) such that the infusion aperture is between the first occluder and the second occlude (paragraph 0013, lines 7-10, the opening in element 20 has to be located between elements 3 and 5 in order to deliver the fluid to an isolated segment of the vessel), the first occluder and the second occluder being configured to isolate a segment of a vessel (paragraph 0013, lines 7-10); an adapter (see “A” in fig. 2A above) coupled to the outer catheter 4, the adapter including a first port (see “FP” in figure 2A above) and a second port (see “SP” in figure 2A above) but is silent regarding the first port in fluid communication with the first lumen through which a therapeutic agent can be conveyed to the segment of the vessel isolated by the first occluder and the second occluder, the second port in fluid communication with the second lumen. However, Zadno-Azizi teaches a design of a catheter (figure 3) comprising an adapter 112 having the first port 120 and the second port 123, the first port in fluid communication with the lumen 130 through which a therapeutic agent can be conveyed to a segment of the vessel (paragraph 0068, lines 14-17) and the second port 123 in fluid communication with the lumen 130 for the purpose of using the ports to introduce therapeutic agents into the patient’s body and the medical device (paragraph 0068, lines 2-17). Examiner further construes that even though Zadno-Azizi discloses the use of different port to access same lumen 130, Garrison discloses different lumen and ports. Therefore, one of ordinary skill in the art, modifying the device of Garrison in view of Zadno-Azizi would result in having the first port in fluid communication with the first lumen through which a therapeutic agent can be conveyed to a region of the vessel isolated by the first occluder and the second occluder, the second port in fluid communication with the second lumen. Therefore, it would have been prima facie obvious to one of ordinary skill in the art, before the effective filing of the claimed invention to define the function of the ports of the device of Garrison to incorporate the first port in fluid communication with the first lumen through which a therapeutic agent can be conveyed to a region of the vessel isolated by the first occluder and the second occluder, the second port in fluid communication with the second lumen as taught by Zadno-Azizi for the purpose of using the ports to introduce therapeutic agents into the patient’s body and the medical device (paragraph 0068, lines 2-17). Garrison is silent regarding a handle, configured to allow for single handed operation of the apparatus, the handle comprising an actuator on the handle that includes a set of protrusions that are configured to be sequentially engaged as the actuator is moved between a plurality of predetermined settings corresponding to predetermined distances between an end portion of the outer catheter and an end portion of the inner catheter, further wherein the handle comprises a visual indicator of the predetermined settings indicating a position of the actuator and configured to determine a desired distance to move the actuator. However, Andreas teaches a design of devices and methods for controlling and indicating the length of an interventional element comprising a handle 28 (figure 2A, examiner construes element 56 being part of element 28), configured to allow for single handed operation of the apparatus (element 28 would allow single handed operation), the handle 28 comprising an actuator 58 on the handle that includes a set of markings 60 that are configured to be sequentially engaged as the actuator is moved between a plurality of predetermined settings (paragraph 0063, paragraph 0065, lines 32-35) corresponding to predetermined distances between an end portion of the outer catheter 38 and an end portion of the inner catheter 36, further wherein the handle 28 comprises a visual indicator 60 (paragraph 0073, lines 11-13) of the predetermined settings indicating a position of the actuator and configured to determine a desired distance to move the actuator for the purpose of having improved ways of controlling and providing indication of balloon length (paragraph 0010). Therefore, it would have been prima facie obvious to one of ordinary skill in the art, before the effective filing of the claimed invention to modify the apparatus of Garrison to incorporate a handle, configured to allow for single handed operation of the apparatus, the handle comprising an actuator on the handle that includes a set of protrusions that are configured to be sequentially engaged as the actuator is moved between a plurality of predetermined settings corresponding to predetermined distances between an end portion of the outer catheter and an end portion of the inner catheter, further wherein the handle comprises a visual indicator of the predetermined settings indicating a position of the actuator as taught by Andreas for the purpose of having improved ways of controlling and providing indication of balloon length (paragraph 0010). While Andreas discloses the visual indicator 60 could include alphanumeric symbols or other appropriate indicators (paragraph 0063, lines 2-5), Garrison modified in view of Andreas is silent regarding a set of protrusions and wherein the visual indicator corresponds with the protrusions associated with the plurality of predetermined settings. However, Looper teaches a design of a catheter allowing variable dosing including a set of markings and visual indicator 21 (figure 1) comprising a set of protrusions (paragraph 0017, lines 1-4) and wherein the visual indicator (examiner construes that “visual indicator” corresponds to the numbers associated with the lines and protrusions refers to lines in graduated marking) corresponds with the protrusions associated with the plurality of predetermined settings for the purpose of using a well-known approaches in placing the protrusions and visual markers on medical device (paragraph 0017, figure 1). Therefore, it would have been prima facie obvious to one of ordinary skill in the art to modify the set of markings and visual indicator of Garrison in view of Andreas to incorporate a set of protrusions and wherein the visual indicator corresponds with the protrusions associated with the plurality of predetermined settings as taught by Looper for the purpose of using a well-known approach in placing the protrusions and visual markers on medical device (paragraph 0017, figure 1). Regarding claim 13, Garrison discloses the distance between the first occluder and the second occluder is adjustable (paragraph 0065, lines 5-8). However, Garrison does not explicitly disclose the distance between the first occluder and the second occluder is adjustable between 3 cm and 15 cm. There is no evidence of record that establishes that changing the distance would result in a difference in a function of Garrison. Further, a person having ordinary skill in the art, being faced with modifying the distance between the first occluder and the second occluder would have a reasonable expectation of success in making such a modification and it appears that the device would function as intended being given the claimed distance range. Lastly, applicant has not disclosed that the claimed range solves any stated problem, indicating that the distance “may” be within the claimed range, and offering other ranges (3 cm to 22 cm, paragraph 0073) and therefore, there appears to be no criticality placed on the range as claimed such that it produces an unexpected result. Therefore, it would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to modify the distance of Garrison to have the distance between 3 cm and 15 cm as an obvious matter of design choice within the skill of the art. Regarding claim 14, Garrison discloses further comprising a pressure sensor (paragraph 0010, lines 12-15, paragraph 0045, lines 11-15) configured to measure a fluid pressure within the segment of the vessel isolated by the first occluder and the second occluder. Regarding claim 16, Garrison discloses wherein the first occluder 3 and the second occluder 5 are each configured to be transitioned from the collapsed configuration (configuration where elements 3 and 5 are not expanded) to an expanded configuration (configuration where elements 3 and 5 are inflated), the first occluder 3 and the second occluder 5 isolating the segment of the vessel when each of the first occluder and the second occluder are in the expanded configuration (see figure 8A, the embodiment shown in figure 8A is different but the function of all the disclosed embodiments are the same). Regarding claim 17, Garrison discloses the adapter includes a third port (any of the unlabeled port in 2A above) and discloses the lumen 14 in communication with the second occluder but is silent regarding a third port fluidically coupled to the second occluder, the third port configured to convey an inflation medium to the second occluder to transition the second occluder from its collapsed configuration to its expanded configuration. However, Zadno-Azizi discloses a third port 118 fluidically coupled to the second occluder 126, the third port 118 configured to convey an inflation medium to the second occluder to transition the second occluder from its collapsed configuration to its expanded configuration (paragraph 0068, lines 11-14) for the purpose of using the ports to control the inflation of the second occluder (paragraph 0068, lines 11-14). Therefore, it would have been prima facie obvious to one of ordinary skill in the art, before the effective filing of the claimed invention to modify the use of ports of Garrison to include a third port fluidically coupled to the second occluder, the third port configured to convey an inflation medium to the second occluder to transition the second occluder from its collapsed configuration to its expanded configuration as taught by Zadno-Azizi for the purpose of using the ports to control the inflation of the second occluder (paragraph 0068, lines 11-14). Regarding claim 18, Garrison discloses the use of pressure sensor for monitoring an infusion pressure within the isolated segment of the vessel between the first occluder and the second occluder (paragraph 0010, lines 12-15, paragraph 0045, lines 11-15) but is silent regarding comprising a pressure monitor in line with the infusion aperture and through which an infusion pressure within the isolated segment of the vessel between the first occluder and the second occluder can be measured in one embodiment. However, Garrison discloses in a different embodiment (figure 8B) comprising aa pressure monitor in line with the infusion aperture 34 and through which an infusion pressure within the isolated segment of the vessel between the first occluder and the second occluder can be measured (paragraph 0056, lines 5-12) for the purpose of regulating the pressure if needed using the measured pressure (paragraph 0018). Therefore, it would have been prima facie obvious to one of ordinary skill in the art, before the effective filing of the claimed invention to modify the apparatus of one embodiment of Garrison to include a pressure monitor in line with the infusion aperture and through which an infusion pressure within the isolated segment of the vessel between the first occluder and the second occluder can be measured as taught by different embodiment of Garrison for the purpose of regulating the pressure if needed using the measured pressure (paragraph 0018). Regarding claim 19, Garrison discloses wherein a distance between the first occluder and the second occluder being adjustable (paragraph 0006, lines 11-15). Regarding claim 20, Garrison discloses an apparatus (figure 1A) comprising: an inner catheter 2 defining an inner catheter lumen 17 (figures 3, 4, 7) configured to receive a guidewire (paragraph 0045, lines 8-11); a first occluder 3 coupled to the inner catheter 2 at a first axial location (location where element 2 is positioned with respect to element 3) along the inner catheter 2; an outer catheter 4 including a side wall (wall of element 19A forming element 20 in figure 5) defining an infusion aperture (an aperture in element 20 that delivers the fluid, furthermore, claim recites the term “defining” which do not necessarily mean to have an infusion aperture located on sidewall only, instead examiner construes the term “defining” as being able to define at least a portion of an aperture. In Garrison, sidewall of element 20 is at least partially defining the opening through which fluid gets delivered), the outer catheter 4 defining a first lumen 20 in fluid communication with the infusion aperture (opening in element 20 delivering the fluid to the patient) and a second lumen 13 (paragraph 0047), at least a portion of the inner catheter 2 being slidably disposed within the second lumen 13; a second occluder 5 coupled to the outer catheter 4 at a second axial location (location of element 5 with respect to element 4) along the catheter device (figure 1A), the second axial location spaced apart from the first axial location (figure 1A) such that the infusion aperture is between the first occluder and the second occluder (paragraph 0013, lines 7-10, the opening in element 20 has to be located between elements 3 and 5 in order to deliver the fluid to an isolated segment of the vessel), the first occluder and the second occluder being configured to isolate a segment of a vessel (paragraph 0013, lines 7-10), wherein a distance between the first occluder and the second occluder being adjustable (paragraph 0006, lines 11-15); and an adapter (see “A” in fig. 2A above) coupled to the outer catheter 4, the adapter including a first port (see “FP” in figure 2A above) and a second port (see “SP” in figure 2A above); a pressure transducer (paragraph 0045, lines 1-3) configured to detect a pressure within the target vessel between the first occluder 3 and the second occluder 5 and configured to guide delivery of the therapeutic material to the one or more target vessels (paragraph 0019, lines 2-13, “configured to guide delivery” is pretty broad term and would also mean to recite rate of delivery to prevent exceeding maximum pressure as explained by Garrison) but is silent regarding the first port in fluid communication with the first lumen through which a therapeutic agent can be conveyed to a segment of the vessel isolated by the first occluder and the second occluder, the second port in fluid communication with the second lumen. However, Zadno-Azizi teaches a design of a catheter (figure 3) comprising an adapter 112 having the first port 120 and the second port 123, the first port in fluid communication with the lumen 130 through which a therapeutic agent can be conveyed to a segment of the vessel (paragraph 0068, lines 14-17) and the second port 123 in fluid communication with the lumen 130 for the purpose of using the ports to introduce therapeutic agents into the patient’s body and the medical device (paragraph 0068, lines 2-17). Examiner further construes that even though Zadno-Azizi discloses the use of different port to access same lumen 130, Garrison discloses different lumen and ports. Therefore, one of ordinary skill in the art, modifying the device of Garrison in view of Zadno-Azizi would result in having the first port in fluid communication with the first lumen through which a therapeutic agent can be conveyed to a region of the vessel isolated by the first occluder and the second occluder, the second port in fluid communication with the second lumen. Therefore, it would have been prima facie obvious to one of ordinary skill in the art, before the effective filing of the claimed invention to define the function of the ports of the device of Garrison to incorporate the first port in fluid communication with the first lumen through which a therapeutic agent can be conveyed to a region of the vessel isolated by the first occluder and the second occluder, the second port in fluid communication with the second lumen as taught by Zadno-Azizi for the purpose of using the ports to introduce therapeutic agents into the patient’s body and the medical device (paragraph 0068, lines 2-17). Garrison is silent regarding a handle, configured to allow for single handed operation of the apparatus, the handle comprising an actuator on the handle that includes a set of protrusions that are configured to be sequentially engaged as the actuator is moved between a plurality of predetermined settings corresponding to predetermined distances between an end portion of the outer catheter and an end portion of the inner catheter, further wherein the handle comprises a visual indicator of the predetermined settings indicating a position of the actuator and configured to determine a desired distance to move the actuator. However, Andreas teaches a design of devices and methods for controlling and indicating the length of an interventional element comprising a handle 28 (figure 2A, examiner construes element 56 being part of element 28), configured to allow for single handed operation of the apparatus (element 28 would allow single handed operation), the handle 28 comprising an actuator 58 on the handle that includes a set of markings 60 that are configured to be sequentially engaged as the actuator is moved between a plurality of predetermined settings (paragraph 0063, paragraph 0065, lines 32-35) corresponding to predetermined distances between an end portion of the outer catheter 38 and an end portion of the inner catheter 36, further wherein the handle 28 comprises a visual indicator 60 (paragraph 0073, lines 11-13) of the predetermined settings indicating a position of the actuator and configured to determine a desired distance to move the actuator for the purpose of having improved ways of controlling and providing indication of balloon length (paragraph 0010). Therefore, it would have been prima facie obvious to one of ordinary skill in the art, before the effective filing of the claimed invention to modify the apparatus of Garrison to incorporate a handle, configured to allow for single handed operation of the apparatus, the handle comprising an actuator on the handle that includes a set of protrusions that are configured to be sequentially engaged as the actuator is moved between a plurality of predetermined settings corresponding to predetermined distances between an end portion of the outer catheter and an end portion of the inner catheter, further wherein the handle comprises a visual indicator of the predetermined settings indicating a position of the actuator as taught by Andreas for the purpose of having improved ways of controlling and providing indication of balloon length (paragraph 0010). While Andreas discloses the visual indicator 60 could include alphanumeric symbols or other appropriate indicators (paragraph 0063, lines 2-5), Garrison modified in view of Andreas is silent regarding a set of protrusions and wherein the visual indicator corresponds with the protrusions associated with the plurality of predetermined settings. However, Looper teaches a design of a catheter allowing variable dosing including a set of markings and visual indicator 21 (figure 1) comprising a set of protrusions (paragraph 0017, lines 1-4) and wherein the visual indicator (examiner construes that “visual indicator” corresponds to the numbers associated with the lines and protrusions refers to lines in graduated marking) corresponds with the protrusions associated with the plurality of predetermined settings for the purpose of using a well-known approaches in placing the protrusions and visual markers on medical device (paragraph 0017, figure 1). Therefore, it would have been prima facie obvious to one of ordinary skill in the art to modify the set of markings and visual indicator of Garrison in view of Andreas to incorporate a set of protrusions and wherein the visual indicator corresponds with the protrusions associated with the plurality of predetermined settings as taught by Looper for the purpose of using a well-known approach in placing the protrusions and visual markers on medical device (paragraph 0017, figure 1). Claim(s) 15 is rejected under 35 U.S.C. 103 as being unpatentable over Garrison et al. (US 2005/0059931 A1) in view of Andreas et al. (US 2005/0149159 A1) in view of Zadno-Azizi et al. (US 2002/0016565) in view of Looper et al. (US 2013/0281971 A1) and further in view of Slater et al. (US 2006/0149218 A1). Regarding claim 15, modified Garrison/Zadno-Azizi (hereinafter referred as “modified Garrison ‘31”) discloses the claimed invention substantially as claimed, as set forth above in claim 12. Modified Garrison ’31 is silent regarding further comprising a seal coupled to the outer catheter between the inner catheter and the outer catheter, the seal configured to prevent therapeutic material from entering the second lumen of the outer catheter. However, Slater teaches a design (figure 34) of treating the interior of a blood vessel comprising a seal 1104 (figure 34) coupled to the outer catheter 1100 between the inner catheter 1102 and the outer catheter 1100, the seal 1104 configured to prevent therapeutic material (material infused into element 1100) from entering the second lumen of the outer catheter for the purpose of preventing the flow of the fluid out from the distal end of the second lumen (figure 34, paragraph 0152, lines 1-4). Therefore, it would have been prima facie obvious to one of ordinary skill in the art, before the effective filing of the claimed invention to modify the apparatus of modified Garrison ’31 to incorporate further comprising a seal coupled to the outer catheter and configured to prevent therapeutic material from entering the second lumen of the outer catheter as taught by Slater for the purpose of preventing the flow of the fluid out from the distal end of the second lumen (figure 34, paragraph 0152, lines 1-4). Response to Arguments Applicant’s arguments with respect to claims 2-20 (pages 7-12) have been considered but are moot because the arguments do not apply in view of the present rejection. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to NILAY J SHAH whose telephone number is (571)272-9689. The examiner can normally be reached Monday-Thursday 8:00 AM-4:30 PM EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, CHELSEA STINSON can be reached at 571-270-1744. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NILAY J SHAH/Primary Examiner, Art Unit 3783
Read full office action

Prosecution Timeline

Jan 03, 2023
Application Filed
Jul 31, 2023
Response after Non-Final Action
Feb 14, 2025
Non-Final Rejection — §103
Aug 20, 2025
Response Filed
Oct 03, 2025
Final Rejection — §103
Dec 08, 2025
Response after Non-Final Action
Dec 30, 2025
Request for Continued Examination
Jan 05, 2026
Response after Non-Final Action
Jan 30, 2026
Non-Final Rejection — §103
Apr 07, 2026
Examiner Interview Summary
Apr 07, 2026
Applicant Interview (Telephonic)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12589220
Instrument Delivery Device with Nested Housing
2y 5m to grant Granted Mar 31, 2026
Patent 12576210
PREFILLED SYRINGE INJECTOR
2y 5m to grant Granted Mar 17, 2026
Patent 12569658
INTRANASAL AND OLFACTORY DELIVERY DEVICES AND METHODS OF USE
2y 5m to grant Granted Mar 10, 2026
Patent 12551617
DEVICE, SYSTEM, AND METHOD FOR APPLYING A PHARMACEUTICAL FLUID
2y 5m to grant Granted Feb 17, 2026
Patent 12551614
Trigger Arrangement for an Infusion Device
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
77%
Grant Probability
99%
With Interview (+47.4%)
3y 3m
Median Time to Grant
High
PTA Risk
Based on 571 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month